MSH|^~\&|IGENE|MFT|EPIC|MFT|20251014155942||ORU^R01|ORIE-251014-9|T|2.3PID||9737383206|||LIVERPOOL^Ned||19420618|M|||^^^^L18 9TNORC|RE|LRI-5286710001|||||||||||||||||||Liverpool Womens^^^^^REP^^^ODSOBR|1|Acme23469|Gen825750|R210.2^Inherited MMR deficiency (Lynch syndrome)^England-GenomicTestDirectory|R|201608030830|201608091650|OBX|1|TX|53577-3^Reason for study^LN|1|Patient may have Lynch Syndrome|OBX|2|CWE|51967-8^Genetic disease(s) assessed^LN|1|C0009405^Lynch syndrome^MedGen-Dis|OBX|3|CWE|51958-7^Transcript reference sequence [Identifier]^LN|1|NM_000249^NM_000249^RefSeq-T|OBX|4|CNE|48018-6^Gene studied^LN|1.a|7127^MLH1^HGNC-Symb|OBX|5|TX|81293-3^Description of ranges of DNA sequences examined^LN|1|Bi-directional sequence analysis was performed to test for the presence of a mutation in all coding regions and intron/exon boundaries of the MLH1 gene.|OBX|6|CNE|51968-6^Discrete variation analysis overall interpretation^LN|1|LA6576-8^Positive^LN|OBX|7|CWE|83006-7^Deletion-duplication overall interpretation^LN|1|LA26803-9^No deletion duplications detected in studied regions^LN|OBX|8|FT|51969-4^Full narrative report^LN|1|Result SummaryPositive \.br\\.br\ Result- The following heterozygous alteration was identified: Amino Acid change: p.R497PfsX6 (Arg497ProfsX6) DNA change: c.1489dupC (g.37070354) Classification: PATHOGENIC.\.br\\.br\ Interpretation - The c.1489dupC (p.R497PfsX6) alteration is a known pathogenic mutation. This result is consistent with a diagnosis of Lynch syndrome for this individual. \.br\\.br\ Method â€“ Bi-directional sequence analysis was performed to test for the presence of a mutation in all coding regions and intron/exon boundaries of the MLH1 gene. Array comparative genomic hybridization (aCGH) was used to test for the presence of large deletions and duplications in this gene.|OBX|9|CWE|62374-4^Human reference sequence assembly^LN|1|LA14029-5^GRCh37^LN|OBX|10|NM|82115-7^dbSNP version^LN|1|147|Attributes of Discrete Genetic Variants: Report Section 2OBX|11|CNE|83005-9^Variant Category^LN|2a|LA26801-3^Simple Variant^LN|OBX|12|CNE|81252-9^Discrete genetic variant^LN|2a|89753^NM_000249.3(MLH1):c.1489dupC (p.Arg497Profs)^ClinVar-V|OBX|13|CWE|48018-6^Gene studied^LN|2a|89753^MLH1^HGNC-Symb|OBX|14|CWE|51958-7^Transcript RefSeq ID^LN|2a|NM_000249.3^NM_000249.3^RefSeq-T|OBX|15|CWE|41103-3^Transcript DNA Change(cHGVS)^LN|2a|c.1489dupC^c.1489dupC^HGVS.c|OBX|16|CWE|48005-3^Amino acid change p.HGVS^LN|2a|p.Arg497Profs^p.Arg497Profs^HGVS.p|OBX|17|CWE|48019-4^DNA change type^LN|2a|LA6686-5^Duplication^LN|OBX|18|CWE|48006-1^Amino acid change type^LN|2a|LA6694-9^Frameshift^LN|OBX|19|CWE|48013-7^Genomic reference sequence^LN|2a|NG_007109.2:g.40514dupC^NG_007109.2:g.40514dupC^RefSeq-G|OBX|20|CWE|81290-9^Genomic DNA change (gHGVS)^LN|2a|NC_000003.11^NC_000003.11^HGVS.g|OBX|21|ST|69547-8^Genomic ref allele^LN|2a|C|OBX|22|NR|81254-5^Genomic allele start-end^LN|2a|37070354^37070354|OBX|23|ST|69551-0^Genomic alt allele^LN|2a|CC|OBX|24|CNE|81255-2^dbSNP ID^LN|2a|rs63751031^rs63751031^dbSNP|OBX|25|CWE|48001-2^Cytogenetic (chromosome) location^LN|2a|3p22.2^3p22.2^Chrom-Loc|OBX|26|CNE|48002-0^Genomic source class^LN|2a|LA6683-2^Germline^LN|OBX|27|CWE|53037-8^Variant analysis method^LN|2a|LA26398-0^Sequencing^LN|OBX|28|CNE|53037-8^Genetic variation clinical significance^LN|2a|LA6668-3^Pathogenic^LN|OBX|29|CNE|69548-6^Genomic variant assessment^LN|2a|LA9633-4^Present^LN|OBX|30|CWE|81259-4^Probable associated phenotype^LN|2a|C0009405^Lynch syndrome^MedGen-Dis|OBX|31|CNE|53034-5^Allelic state^LN|2a|LA6706-1^Heterozygous^LN|